Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Ochsner Clinic Foundation

New Orleans, Louisiana 70121, United StatesNot linked to an institution yet

57running trials
34closed trials

The trials here

What the 92 trials at this site are about, from their registry records.

Conditions: Colorectal cancer11 trials
Lung cancer9 trials
Liver and biliary tract cancer8 trials
Bladder cancer6 trials
Prostate cancer6 trials
Aortic stenosis5 trials
Kidney cancer5 trials
Multiple sclerosis5 trials
Childhood cancers4 trials
Chronic lymphocytic leukaemia4 trials
Endometrial cancer4 trials
Melanoma4 trials
and 34 more
Phase: Phase 331 trials
Phase 217 trials
Phase 111 trials
Phase 1/29 trials
Phase 2/33 trials
Phase 42 trials
Status: Active, not recruiting35 trials
Completed22 trials
Recruiting21 trials
Terminated12 trials
Not yet recruiting1 trial
Suspended1 trial
Lead sponsor: Pfizer8 trials
Eli Lilly and Company7 trials
Edwards Lifesciences5 trials
Janssen Research & Development, LLC5 trials
Novartis Pharmaceuticals5 trials
and 56 more

Running trials

Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426· Phase 3· Novartis Pharmaceuticals· Source
Contact: Anna Leonard-Leumas
Recruiting
Continuous Dual Aspiration Technique With Zoom System for Stroke
NCT07491952· Imperative Care, Inc.· Source
Contact: Jessica Henry
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Brian Halbert (principal investigator)
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: Katrina Wade (principal investigator)
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT06607458· Phase 2· Delcath Systems Inc.· Source
Contact: Matthew Cooney, MD
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013· Phase 1/2· Eli Lilly and Company· Source
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Ralph Millett (principal investigator)
Active, not recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830· Phase 2· Neuron23 Inc.· Source
Contact: Anna Leonard-Leumas
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
NCT06516653· Laminate Medical Technologies· Source
Contact: Shannon Williams
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
ADVENT Post Approval Study
NCT06431815· Boston Scientific Corporation· Source
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· Phase 3· Gilead Sciences· Source
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Contact: Clinical Trial Disclosure & Transparency
Recruiting
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
NCT06263426· Johns Hopkins University· Source
Contact: Jonathan Hand, MD
Active, not recruiting
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
NCT06014762· Phase 1· Poseida Therapeutics, Inc.· Source
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698· Hamilton Health Sciences Corporation· Source
Contact: Richard Zweifler, MD (principal investigator)
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565· Phase 2· Boston Scientific Corporation· Source
Active, not recruiting
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NCT05953337· ABK Biomedical· Source
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941· Phase 4· Novartis Pharmaceuticals· Source
Contact: Stephen Bardot (principal investigator)
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107· Phase 2· Zucara Therapeutics Inc.· Source
Contact: Teva Williams
Active, not recruiting
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739· Phase 1· Sapience Therapeutics· Source
Active, not recruiting
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NCT03862430· Phase 2· NuvOx LLC· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370· Phase 1/2· BeiGene· Source
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
NCT05506943· Phase 2/3· Compass Therapeutics· Source
Active, not recruiting
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773· Phase 3· Fidia Farmaceutici s.p.a.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130· Phase 1· Pfizer· Source
Recruiting
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
NCT05135091· Phase 3· Neurona Therapeutics· Source
Contact: Neydin Osorio, BS, CRC
Active, not recruiting
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Contact: Jessica Henry
Recruiting
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT05051722· Mayo Clinic· Source
Contact: Ashley Samuel, CRC
Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Recruiting
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
NCT06719583· Michael J. Fox Foundation for Parkinson's Research· Source
Contact: Dominique Thomas
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
NCT04215146· Phase 2· Oncolytics Biotech· Source
Active, not recruiting
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105· Phase 2· Vyriad, Inc.· Source
Active, not recruiting
Clinical Trial Multi-analyte Blood Test
NCT03694600· Helio Genomics· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
9-ING-41 in Patients With Advanced Cancers
NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
NCT03695978· Octapharma· Source
Contact: Cristina Solomon, MD
Active, not recruiting
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
NCT03319940· Phase 1· Amgen· Source

Showing 50 of 57.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Stroke3 recruiting
Bladder cancer2 recruiting
Chronic lymphocytic leukaemia2 recruiting
Colorectal cancer2 recruiting
Ovarian cancer2 recruiting
Parkinson disease2 recruiting
Aortic stenosis1 recruiting
Atrial fibrillation1 recruiting
Cervical cancer1 recruiting
Chronic kidney disease1 recruiting
Endometrial cancer1 recruiting
Epilepsy1 recruiting
HIV1 recruiting
Immune thrombocytopenia (ITP)1 recruiting
Lung cancer1 recruiting
Prostate cancer1 recruiting
Type 1 diabetes1 recruiting

Closed trials

Terminated
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711· Phase 3· Mannkind Corporation· Source
Terminated
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
NCT06488911· Phase 3· Intercept Pharmaceuticals· Source
Completed
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
NCT06001177· Phase 2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source
Completed
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
NCT05536297· Phase 3· Astellas Pharma Global Development, Inc.· Source
Terminated
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
NCT05497453· Phase 1/2· Omega Therapeutics· Source
Terminated
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
NCT05062980· Phase 1· Genprex, Inc.· Source
Terminated
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04958785· Phase 2· Gilead Sciences· Source
Completed
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
NCT04825288· Phase 1/2· XBiotech, Inc.· Source
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922· Phase 1/2· Sellas Life Sciences Group· Source
Contact: James Dean
Recruiting
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141· Phase 3· Pfizer· Source
Completed
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT05230186· TScan Therapeutics, Inc.· Source
Completed
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
NCT04649359· Phase 2· Pfizer· Source
Completed
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
NCT04602390· Phase 1· Anokion SA· Source
Completed
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
NCT04474470· Phase 1/2· TyrNovo Ltd.· Source
Completed
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
NCT04321031· Phase 2· Pfizer· Source
Completed
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT04262856· Phase 2· Arcus Biosciences, Inc.· Source
Completed
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745· Phase 4· Eli Lilly and Company· Source
Completed
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· Phase 3· Ipsen· Source
Completed
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
NCT03836209· Phase 2· PrECOG, LLC.· Source
Completed
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
NCT03972306· Phase 1· Hoffmann-La Roche· Source
Terminated
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
NCT03894215· Phase 2· Agenus Inc.· Source
Completed
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT03872947· Phase 1· Toray Industries, Inc· Source
Completed
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
NCT03901963· Phase 3· Janssen Research & Development, LLC· Source
Completed
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
NCT03734393· Johns Hopkins University· Source
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
NCT03592472· Phase 3· Xynomic Pharmaceuticals, Inc.· Source
Contact: Sophia Paspal, Ph.D.
Completed
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
NCT03269136· Phase 1· Pfizer· Source
Terminated
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
NCT03283826· Phase 1/2· Atara Biotherapeutics· Source
Terminated
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
NCT03288545· Phase 1/2· Astellas Pharma Global Development, Inc.· Source
Terminated
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
NCT03248492· Phase 2· Daiichi Sankyo· Source
Completed
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764· Phase 1· Inspirna, Inc.· Source
Terminated
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
NCT03061305· Strata Oncology· Source
Completed
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT02576509· Phase 3· Bristol-Myers Squibb· Source
Completed
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate
NCT03222128· Edwards Lifesciences· Source
Completed
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk
NCT01314313· Edwards Lifesciences· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error